Insilico Medicine vs Alan

By valuation, Alan is the larger company at $5.8B versus $1.2B — a 4.9x difference. Size can also be measured by team: Insilico Medicine employs 350 people while Alan has 500-1000 employees.

Alan has raised more in total funding at $750M, compared to Insilico Medicine's $500M — a gap of $250M. Combined, the two companies have completed 4 known funding rounds.

Alan leads with an Awaira Score of 83/100, while Insilico Medicine sits at 67/100. That 16-point gap reflects real differences in funding, scale, and traction — it's not a vanity metric.

Insilico Medicine was founded by Alex Zhavoronkov in 2014. Alan was founded by Jean-Charles Samuelian in 2016. Visit each company's profile on Awaira for a full founder biography.

Insilico Medicine: Insilico Medicine is an AI-driven drug discovery and development company founded in 2014 and headquartered in the USA. The company applies artificial intelligence, machine learning, and generative models to accelerate the identification and optimization of drug candidates across multiple therapeutic areas. Its core platform integrates physics-based modeling with deep learning to predict molecular properties, identify disease targets, and design novel compounds with improved efficacy and reduced toxicity. The company operates across several segments: AI-powered target identification, lead optimization, and clinical trial optimization. Notable applications include oncology, aging-related diseases, and fibrosis. Insilico Medicine has demonstrated its technology through partnerships with pharmaceutical companies and biotech firms seeking to reduce drug development timelines and costs. The platform has been applied to various disease targets, with some candidates advancing through development stages. With $403 million in total funding and a valuation of $1.2 billion, Insilico Medicine represents a significant player in the AI healthcare sector. The company went public, reflecting investor confidence in its technology platform and business model. Its competitive position centers on the integration of generative AI models with molecular biology expertise. The company competes alongside other AI drug discovery platforms while differentiating through its aging research focus and established pharma partnerships. Insilico Medicine uniquely combines generative AI with longevity research, targeting age-related diseases while maintaining traditional pharma collaboration channels. Alan: Alan is an AI-powered health insurance platform that combines employer group health insurance products with a digital health companion application, using AI to personalise member health recommendations, streamline claims processing, and provide on-demand access to telehealth and mental health resources. The Paris company holds full insurance carrier status in France, Belgium, and Spain, operating as a licensed insurer rather than a distribution intermediary.\n\nThe company raised approximately $220 million including a Series D round from investors including Temasek, Coatue, and Index Ventures, reaching a valuation of approximately $1.4 billion. Alan reports over half a million members across its markets, covering employees at several thousand companies including Stripe, Spendesk, and Vinted, with strong growth in SME employer sales driven by its digital-first enrolment and claims experience. The Alan app provides members with health navigation, symptom checking, and AI-generated health content in addition to insurance card and claims management functionality.\n\nAlan competes in the European digital health insurance market against traditional mutuals including Malakoff Humanis and AG2R La Mondiale, as well as digital health insurers including Henner and Oscar Health in the US context. Its vertical integration as a licensed insurer combined with a technology platform differentiates it from insurtechs that distribute existing insurer products through digital channels, giving Alan full control over the member experience and claims economics. The company is considered one of the most significant French technology companies building in regulated financial services.

Insilico Medicine got there first, launching in 2014 — that's 2 years of extra runway. Alan didn't arrive until 2016. In AI, that kind of head start means more training data, deeper customer relationships, and a bigger talent moat.

Insilico Medicine has about 350 employees; Alan has about 500-1000. A bigger team usually means more revenue or heavier VC backing, but in AI, small teams can build at massive scale.

Yes — they're direct rivals. Both Insilico Medicine and Alan compete in AI Healthcare, targeting many of the same buyers. If you're evaluating one, you should be looking at the other.